Literature DB >> 11990464

Tumor cell prothrombotic properties.

A Falanga1.   

Abstract

Thrombin generation and fibrin formation are constantly determined in patients with malignancy, who are at increased risk of thromboembolic complications. Most importantly, fibrin formation is also involved in the processes of tumor spread and metastasis. Activation of blood coagulation in cancer is a complex phenomenon, involving many different pathways of the hemostatic system and numerous interactions of the tumor cell with other blood cells, including platelet, monocyte and endothelial cell. Tumor cells possess the capacity to interact with all parts of the hemostatic system. They can directly activate the coagulation cascade by producing their own procoagulant factors or they can stimulate the prothrombotic properties of other blood cell components. All of the mechanisms are not entirely understood, however research studies in the last ten years have greatly improved our knowledge of tumor-promoted pro-thrombotic functions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11990464

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  4 in total

Review 1.  Impact of venous thromboembolism and anticoagulation on cancer and cancer survival.

Authors:  Nicole M Kuderer; Thomas L Ortel; Charles W Francis
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

2.  Arsenic trioxide downregulates cancer procoagulant activity in MCF-7 and WM-115 cell lines in vitro.

Authors:  Ewelina A Hoffman; Katarzyna Gizelska; Marek Mirowski; Wojciech Mielicki
Journal:  Contemp Oncol (Pozn)       Date:  2015-05-13

3.  Gastrointestinal stromal tumors: Fibrinogen levels are associated with prognosis of patients as blood-based biomarker.

Authors:  Jing Lu; Shuangjiang Chen; Xuqi Li; Guanglin Qiu; Shicai He; Haijiang Wang; Libo Zhou; Yaheng Jing; Xiangming Che; Lin Fan
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

4.  Congenital and acquired thrombotic risk factors in lymphoma patients bearing upper extremities deep venous thrombosis: a preliminary report.

Authors:  Pierpaolo Di Micco; Alferio Niglio; Amalia De Renzo; Anna Lucania; Rosanna Di Fiore; Olga Scudiero; Giuseppe Castaldo
Journal:  J Transl Med       Date:  2004-03-22       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.